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A B S T R A C T
Deficiencies in the lysosomal hydrolase β-galactosidase (β-gal) lead to two distinct diseases: the skeletal disease
Morquio syndrome type B, and the neurodegenerative disease GM1-gangliosidosis. Utilizing CRISPR-Cas9
genome editing, the mouse β-gal encoding gene, Glb1, was targeted to generate both models of β-gal deficiency
in a single experiment. For Morquio syndrome type B, the common human missense mutation W273L (position
274 in mice) was introduced into the Glb1 gene (Glb1W274L), while for GM1-gangliosidosis, a 20 bp mutation was
generated to remove the catalytic nucleophile of β-gal (β-gal−/−). Glb1W274L mice showed a significant re-
duction in β-gal enzyme activity (8.4–13.3% of wildtype), but displayed no marked phenotype after one year. In
contrast, β-gal−/− mice were devoid of β-gal enzyme activity (≤1% of wildtype), resulting in ganglioside ac-
cumulation and severe cellular vacuolation throughout the central nervous system (CNS). β-gal−/− mice also
displayed severe neuromotor and neurocognitive dysfunction, and as the disease progressed, the mice became
emaciated and succumbed to the disease by 10months of age. Overall, in addition to generating a novel murine
model that phenotypically resembles GM1-gangliosidosis, the first model of β-galactosidase deficiency with
residual enzyme activity has been developed.
1. Introduction
Typically, when a lysosomal hydrolase is defective, a single lyso-
somal disease arises; however, in the case of the enzyme β-galactosidase
(β-gal, EC 3.2.1.23), mutations in the encoding gene, GLB1, can result
in two lysosomal diseases: GM1-gangliosidosis (OMIM #230500,
230600, 230650), a neurodegenerative disease, and Morquio syndrome
type B (Mucopolysaccharidosis IV B, MPS IVB OMIM #253010), a
skeletal disease. β-gal is responsible for catabolizing the terminal ga-
lactose residue in GM1 ganglioside, its asialo derivative GA1, and the
glycosaminoglycan keratan sulfate [1,2]. The primary substrates that
accumulate in GM1 gangliosidosis are GM1 and GA1 gangliosides,
while in Morquio syndrome type B, keratan sulfate accumulates.
Clinically, GM1-gangliosidosis patients are categorized into one of three
disease severities, 1) infantile, 2) late infantile/juvenile, and 3) adult,
depending upon symptoms and residual β-gal enzyme activity. Those
with the most severe infantile form have minimal or no residual enzyme
activity. Patients usually present with symptoms around 6months of
age, including severe psychomotor and neurocognitive regression, hy-
potonia, macular cherry-red spot, hepatosplenomegaly, skeletal dys-
plasia, coarse facial features, and typically succumb to the disease by
2 years of age [3]. In Morquio syndrome type B, patients have residual
β-gal enzyme activity (1.3–11.9% of normal [4–9]. Morquio syndrome
type B patients present with normal intellect, but suffer from pro-
gressive skeletal dysplasia, short stature, in addition to odontoid hy-
poplasia and corneal clouding [10]. Besides palliative approaches, there
are no available treatments for either of these debilitating diseases.
Animal models are key for the development of novel therapies for
many diseases. In the case of GM1-gangliosidosis, two previously de-
scribed murine models have been developed [11,12], but were not
publicly available when this project was initiated; while no animal
models of Morquio syndrome type B exist. The GM1-gangliosidosis
mouse models that currently exist were developed utilizing embryonic
stem (ES) cell gene targeting to insert the exogenous neomycin re-
sistance gene into the Glb1 locus. The model developed by Hahn et al.
[11] disrupted the gene by inserting the cassette in exon 6, while
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Matsuda et al. [12] targeted exon 15. In both knockout models, β-gal
enzyme activity is nominal compared to controls, which results in ac-
cumulation of GM1 and GA1 gangliosides. While these models have
shown impaired neuromotor function [13,14], neurocognitive testing
has not been conducted.
To create models of β-gal enzyme deficiency for use in the devel-
opment of novel therapies, we employed CRISPR-Cas9 genome editing.
Following a double-stranded DNA break, the eukaryotic cell repairs the
lesion via two pathways: homology directed repair or non-homologous
end joining [15–17]. Here we describe the exploitation of this knowl-
edge to create two novel models of β-galactosidase deficiencies in a
single experiment. To develop a model of Morquio syndrome type B, a
mutation that is commonly found in patients [4–9], GLB1W273L, was
introduced into mice. Additionally, a mutation that abolished β-gal
enzyme activity was created. Mice lacking β-gal activity (β-gal−/−)
recapitulated many aspects of the human disease, including ganglioside
accumulation, cellular vacuolation, and a significantly shortened life-
span. Additionally, β-gal−/− mice had neuromotor impairment, in
addition to a severe neurocognitive deficiency not previously described.
Overall, β-gal−/− mice recapitulated many biochemical, histological,
and phenotypic characteristics of human GM1-gangliosidosis. However,
while mice homozygous for a common Morquio syndrome type B mu-
tation (Glb1W274L) had a present, but significantly reduced, β-gal en-
zyme activity, Glb1W274L mice displayed no observable Morquio syn-
drome type B phenotype up to one year of age.
2. Materials and methods
2.1. Generation of β-gal−/− and Glb1W274L mice by CRISPR-Cas9 embryo
microinjection
β-galactosidase deficient mice were generated by Dr. Dale Cowley
and the Animal Models Core Facility at the University of North Carolina
at Chapel Hill utilizing CRISPR-Cas9 genome editing technology in a
C57BL/6J genetic background. Candidate CRISPR-Cas9 guide RNAs
(gRNA) targeting exon 8 of the mouse Glb1 gene were designed utilizing
Benchling© software (Benchling, Inc) based on the system established
previously by Mali et al. [18]. To increase specificity and reduce the
potential of off-target Cas9 cleavage, truncated 17 nucleotide gRNAs
were designed, as suggested in Fu et al. [19]. gRNAs were produced by
T7 in vitro transcription and validated in vitro by incubating a gRNA,
Cas9 enzyme, and PCR amplified target site together, followed by gel
electrophoresis to determine the extent of in vitro cleavage activity. The
most efficient candidate gRNA was then used for zygote microinjection.
Zygotes for microinjection were produced by super-ovulating
C57BL/6J females by injection of pregnant mare's serum gonadotropin
(PMSG) and human chorionic gonadotropin (HCG) and then mated
with C57BL/6J stud males. 114 one-cell embryos were collected from
the ampulla oviducts the morning after mating and microinjected with
400 nM Cas9 protein, 50 ng/μl gRNA targeting exon 8 of Glb1, and
50 ng/μl donor oligonucleotide. For this experiment, Cas9 protein was
utilized for microinjections to increase on-target efficiency of DNA
cutting [20,21], but to also circumvent the issues with using Cas9
mRNA, including mosaicism at the target site [22]. The donor oligo-
nucleotide was designed to introduce a 2 bp mutation encoding a
tryptophan to leucine substitution commonly found in Morquio syn-
drome type B patients. Of the 114 injected zygotes, 106 were trans-
ferred into 4 pseudopregnant mothers, yielding 24 neonates (Fig. 1A).
Potential founders born from microinjected embryos were screened by
PCR amplification of the Glb1 target site, followed by Sanger sequen-
cing. Of the live offspring, two founders contained a 2 bp mutation
resulting in the W274L amino acid substitution of interest, while an-
other founder contained a 20 bp deletion. These founders were bred to
C57BL/6J wildtype mice for germline transmission of the mutant al-
leles. N1 offspring were screened by PCR-amplification and sequencing
as described for the founder animals. Heterozygous N1 animals were
bred to obtain the wildtype, heterozygous, and homozygous mutant
animals used in this study.
2.2. Animal care and procedures
All animal care and experimental procedures were conducted under
the approval of the Institute Animal Care and Use Committee (IACUC)
of the University of Minnesota. All animals were housed in specific
pathogen-free conditions and genotyped by PCR. C57BL/6J (000664)
animals were purchased from The Jackson Laboratory.
The humane endpoint for these studies was defined as the presence
of limb paralysis, the inability to rear and feed normally, or the loss of
≥15% of peak body weight. For biochemical analysis, animals were
sacrificed by CO2 asphyxiation and perfused transcardially with 20mL
of ice-cold PBS. Animals utilized for histological analysis were further
perfused with 20mL of 10% neutral buffered formalin (NBF). Tissues
isolated for biochemical assays were flash frozen in liquid nitrogen.
2.3. β-galactosidase (β-gal) enzyme assay
β-gal enzyme activity was determined utilizing a fluorometric assay
as previously described [23], with slight modification. Briefly, tissue
samples were homogenized in 1mL of T-PER™ Tissue Protein Extraction
Reagent (Thermo Fisher Scientific, Waltham, MA) with Halt™ Protease
Inhibitor Cocktail (Thermo Fischer Scientific) added to manufacturers
recommendation. To determine β-gal activity, supernatants of the tissue
homogenates were diluted with a 0.2M sodium acetate/0.1 M sodium
chloride buffer (pH 4.3) and 40 μL of each was added in triplicate to a
96-well black round-bottom plate (Corning™, Corning, NY) on ice.
20 μL of a substrate solution containing 1.0mM 4-methylumbelliferyl-
β-D-galactopyranoside (4-MUGal, Millipore-Sigma, St. Louis, MO) was
added to each well, and the plate was incubated for 30min at 37 °C. To
quench the reaction, 200 μL of 1M carbonate buffer (1M sodium car-
bonate to pH 10.7 with 1M sodium bicarbonate) was added. In the
presence of β-gal enzyme, the non-fluorescent 4-MUGal is cleaved and
releases a fluorescent 4-methylumbelliferone (4-MU) molecule. This
fluorescence was measured in a Synergy MX Plate Reader with Gen5
plate reader program (BioTek Instruments, Winooski, VT) with excita-
tion at 360 nm and emission read at 460 nm (80% sensitivity). 4-MU
(Sigma-Millipore) is used to generate a standard curve. β-gal enzyme
activity is expressed in nmol of 4-MU released per hour, per milligram
of protein (nmol/h/mg), which is determined using a Pierce™ BCA
Protein Assay Kit (Thermo Fisher Scientific).
2.4. Histopathological analysis
Following perfusion and fixation with 10% NBF, tissues were pro-
cessed into paraffin wax using standard histology techniques, sectioned
at a thickness of 4 μm, stained with hematoxylin and eosin (H&E), and
evaluated using light microscopy by two A.C.V.P. board-certified pa-
thologists (A.-F. T. and M.G.O'S). Additional evaluation was performed
on selected tissues stained with Luxol fast blue (LFB)/H&E combination
stain, Periodic acid-Schiff (PAS), alcian blue, and toluidine blue using
standard laboratory protocols. For the Glb1W274L mice, the tissues that
were examined include the lungs, liver, heart, spleen, kidney, adrenal
gland, stomach, large and small intestine, brain, eyes, salivary glands,
skeletal muscle, sternum, and femur (including hip and stifle joints).
For β-gal−/− mice, major organs were examined including the brain,
liver, heart, intestines, and pancreas. All work was done at the Masonic
Cancer Center Comparative Pathology Shared Resource laboratory at
the University of Minnesota.
2.5. Ganglioside isolation and quantification
GM1, GA1, GM2, and GM3 ganglioside accumulation in β-gal−/−
animals was quantified by homogenizing the cerebellum (1 g wet
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tissue/10 mL CHAPS solution), cerebral cortex (1 g wet tissue/6mL
CHAPS solution), and hippocampus (1 g wet tissue/10 mL CHAPS so-
lution) in 2% CHAPS solution. Protein precipitation with 200 μL of
methanol was performed to extract gangliosides GM1, GA1, GM2, and
GM3 from 50 μL of homogenate in the presence of internal standards
(GA1 standard converted from N-CD3-Stearoyl-GM1 (18:0) (Matreya,
State College, PA) using methods described in [24]). The 10% study
sample extracts from each tissue type were pooled to prepare a quality
control (QC) sample for that tissue. QC samples were injected every 5
study samples to monitor the instrument performance. Samples re-
ported have a QC coefficient of variance<15%.
Sample analysis was performed with a Shimadzu 20AD HPLC
system coupled to a 6500QTRAP+ mass spectrometer (AB Sciex,
Framingham, MA) operated in positive MRM mode. Data processing
was conducted with Analyst 1.6.3 (Applied Biosystems). Data were
reported as the peak area ratios of the analytes in sample to the cor-
responding internal standards.
2.6. Mouse behavior analysis
At 6months of age, mice were subjected to multiple behavior tests
to assess neuromotor and neurocognitive function. All behavioral ana-
lyses were conducted in the Mouse Behavior Core at the University of
Minnesota.
2.6.1. Neuromotor testing
2.6.1.1. Balance beam. The balance beam protocol was adapted from
[25,26]. Trials were performed on a 1m long wooden beam, held 48 cm
above the table by a platform on one end (start) and a dark enclosure
“safe box” on the other (stop). Before the first trial was conducted each
day, the mouse was habituated for 15 s in the safe box. To begin the
trial, the mouse was placed on the start platform under an aversive light
in a dark room. The latency to cross the beam and enter the enclosure
was measured, in addition to the number of hind foot slips that occur
while crossing the beam. Each mouse was trained on a square beam
(25mm wide) for three days, with four trials per day. On day four, mice
were subjected to two trials on beams of increasing difficulty: 25mm
square beam, followed by 27mm round beam, and lastly the 15mm
wide square beam. Again, latency to cross and number of hind foot slips
were measured. Max trial duration was limited to 60 s.
2.6.1.2. Pole test. The pole test was conducted as previously described
with minor modifications [27]. The test began by placing a mouse head-
upward on a vertical pole (10 cm in diameter; 55 cm tall) wrapped in
athletic tape to assist with grip. Two measurements were taken: Latency
to rotate body to face downward was measured, in addition to total
time to descend the pole and place all 4 paws on the base of the
apparatus inside of the cage, with a maximum test duration of 60 s. If a
mouse failed to make the initial rotation to face downward, 60 s was
recorded for both the turn and total time to descend. If the mouse fell
from the pole during the testing time, it was placed back at the initial
starting point while the time continued until 60 s. Mice were subjected
to a single trial.
2.6.1.3. Rotarod. Rotarod analysis was conducted on an accelerating
rotarod (Ugo Basile, Comerio, Italy), using an adapted protocol
described previously [28]. Briefly, mice were tested for three
consecutive days, undergoing four trials per day, with a minimum
inter-trial duration of 30min. Testing was done on a rotarod
programmed to accelerate from 5 to 50 rpm over a max trial duration
of 300 s. 3–5 mice were placed on the divided rod simultaneously and
the apparatus' counter was started. The trial was considered complete
when 1) the mouse fell off the rotarod and stopped the counter, 2) the
mouse completes two consecutive rotations by holding on to the rod
without walking, or 3) when 300 s elapsed.
2.6.1.4. Inverted screen. Inverted screen testing [29] was completed
utilizing a wire mesh apparatus, approximately 25 cm×25 cm with
25mm2 square openings, placed approximately 30 cm over a cushioned
surface. Testing began by placing the mouse on the wire mesh, which
was then inverted until the animal was completely upside down.
Latency to fall was measured for a max trial duration of 60 s. Mice
Fig. 1. Generation of β-galactosidase deficient mice. (A) Experimental schematic to develop two models of β-galactosidase deficiency in a single experiment utilizing
CRISPR-Cas9 genome editing. (B) Founder animal mutations in exon 8 of β-galactosidase encoding gene Glb1. Two mice had 2 bp mutation resulting in tryptophan to
leucine substitution commonly found in Morquio syndrome type B patients (Glb1W274L, green underlined sequence). Another founder contained a 20 bp deletion (β-
gal−/− Δ20; red asterisks denote stop codons introduced by the deletion). (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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were subjected to 3 trials, with a minimum of 15-min resting period
between trials.
2.6.2. Neurocognitive testing
2.6.2.1. Barnes maze. The Barnes maze [30] was conducted on an
elevated circular platform, 36 in. in diameter, with 20 equally spaced
holes around its perimeter. All of the holes on the platform were
blocked except for one, which contained an opening to an escape box.
The apparatus was placed directly under a bright light source that
served as an aversive stimulus for the mouse to escape the platform.
Visual cues were placed on each of the walls that act as navigational
cues for the mouse. Mice were trained on the Barnes maze for 4 days,
with each mouse subjected to 4 trials per day, with a max of 3min per
trial, and a minimum of 30min between trials. Data was collected
utilizing the ANY-Maze software (Stoelting Co, Wood Dale, IL).
2.6.2.2. Spontaneous alternation T-maze. The spontaneous alternation
T-maze test [31] was utilized to analyze the spatial and working
memory of the animals utilizing a maze consisting of three arms. The
starting arm of the maze contained a small compartment which was
separated from the rest of the maze by a guillotine door. The two choice
arms of the maze contained different visual cues on the end walls for
the mouse to utilize. Testing was done in a dark room with the maze lit
by utilizing a portable canopy light over the choice arms. A mouse was
placed in the start chamber for 5 s, after which the guillotine door is
opened and the mouse was allowed to explore the maze and freely
choose either choice arm. Once the animal's body completely entered
the choice arm, a removable partition was placed behind the mouse,
blocking the animal within the chosen arm for 15 s. This first trial is
referred to as the free choice trial. The animal was then placed back into
the start box for 5 s and the test was repeated, for a total of 11 trials (1
free choice, 10 choice trials). Once all trials were completed, the
percent of correct alternations was calculated. On the following day, the
experiment was repeated and the average percentage of correct
alternations was calculated and reported.
2.7. Statistical analysis
GraphPad Prism 7 (v. 7.0a, GraphPad Software, Inc) was used to
perform all statistical analyses. For all experiments, wildtype, hetero-
zygous, and mutant groups were compared by one-way or two-way
ANOVA followed by Tukey's multiple comparisons test. All values
presented as mean ± SEM.
3. Results
3.1. Generation of β-galactosidase deficient mouse models
A total of 106 blastocysts were implanted into 4 pseudopregnant
female mice, yielding 24 live pups (Fig. 1A). PCR amplification and
sequencing of the targeted site showed that three of the 24 mice con-
tained potential mutations of interest. Two founder mice had under-
gone homology-directed repair to generate the targeted 2 bp missense
mutation of interest at position 274 (Glb1W274L, Fig. 1B). Additionally,
one mouse had undergone non-homologous end joining, which resulted
in a 20 bp deletion within exon 8, yielding 3 premature stop codons in
addition to deleting the catalytic nucleophile of β-galactosidase, the
glutamic acid at position 269 (Glb1Glu269 in mice; Glb1Glu268 in humans)
[32] (β-gal−/−Δ20, Fig. 1B).
One potential pitfall of CRISPR-Cas9 genome editing is off-target
cutting by the Cas9 nuclease. To predict potential off-target sites of
Cas9 DNA cleavage, the CCTOP algorithm [33] was used. Sites of in-
terest were determined by gRNA sequence homology near a potential
PAM sequence. Ten loci were sequenced, 5 containing the NGG PAM
Fig. 2. β-galactosidase enzyme activity. (A) Enzyme activity
in β-gal−/− mouse brain, heart, liver, and spleen (wildtype
n=5, heterozygous n=9, mutant n=7). (B) Enzyme ac-
tivity in Gbl1W274L brain, heart, liver, and spleen (wildtype
n=3, heterozygous n=3, mutant n=4). Data are
mean ± SEM. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001,
****p≤ 0.0001 when comparing mutant mice to wildtype
and heterozygous mice.
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sequence and 5 with a NAG PAM sequence (Supplemental Table 1).
These sequencing results showed that the potential off-target sites were
unedited (data not shown).
In β-gal−/− mice, it was predicted that the deletion of the catalytic
nucleophile and introduction of premature stop codons would result in
loss of β-gal enzyme activity. As expected, β-gal enzyme activity in β-
gal−/− mice was negligible in the brain (1.9 ± 0.2 nmol/h/mg of
protein), heart (0.6 ± 0.5), liver (0.6 ± 0.3), and spleen (3.3 ± 1.0)
in comparison to wildtype (brain, 195.8 ± 30.2; heart, 47.1 ± 7.0;
liver, 190.3 ± 23.5; and spleen, 460.9 ± 27.7) and heterozygous mice
(brain, 95 ± 10.1; heart, 20.9 ± 0.9; liver, 88.7 ± 6.9; and spleen,
264.1 ± 18.6) (Fig. 2A).
Similar to Morquio syndrome type B patients with the GLB1W273L
mutation, homozygous Glb1W274L mutant mice had residual β-gal en-
zyme activity. Offspring from both founders had comparable enzyme
activity levels. In the brain, β-gal enzyme activity in homozygous
Glb1W274L mutant mice (14.5 ± 0.6 nmol/h/mg of protein) was 13.3%
of wildtype activity (108.9 ± 4.0). Similarly, in the heart (4.2 ± 0.4),
liver (10.3 ± 0.8), and spleen (59.8 ± 8.1) of Glb1W274L mice, β-gal
enzyme activity was 9.8%, 8.4%, and 12.4%, of wildtype activity, re-
spectively (heart, 43.2 ± 7.1; liver, 122.5 ± 4.4; and spleen,
480.3 ± 52.0). As expected, carriers of the Glb1W274L mutation have an
intermediate β-gal enzyme activity (brain, 65.0 ± 1.8; heart,
22.0 ± 1.5; liver, 75.3 ± 3.5; and spleen, 322.9 ± 49.2) (Fig. 2B).
Male and female mice from both the Glb1W274L and β-gal−/− lines
are fertile and produce normal litters. However, after 5months of age,
β-gal−/− mice cease breeding. Whether this is due to neurological
symptom onset or another physiological reason has yet to be tested.
3.2. Appearance and survival
At birth, both Glb1W274L and β-gal−/− mice were indistinguishable
from their littermates. At 4months of age, β-gal−/− mice began
showing gait disturbance in their hind limbs, followed by body tremors
and ataxia around 5months. While heterozygous and wildtype female
mice continued to gain weight for the first year of life, female β-gal−/−
mice peaked at 25.3 ± 0.4 g at approximately 33 weeks of age
(~7.5 months), after which their weight declined rapidly (Fig. 3A).
Surprisingly, male β-gal−/− mice became significantly heavier than
their littermates at 25 weeks of age (45.3 ± 1.2 g compared to wild-
type, 40.0 ± 1.2 g and heterozygous, 38.0 ± 0.9 g) (Fig. 3B). Fol-
lowing this peak weight, male β-gal−/− mice began to lose weight
rapidly, similar to female β-gal−/− mice. This decline in weight coin-
cided with the overall decline in health of the β-gal−/− mice.
Similar to the previously published mouse models of GM1-gang-
liosidosis, at 6 months of age, β-gal−/− mice displayed a severe neu-
rological disease phenotype. 6-month-old female (Supplementary
Movie 1) and male (Supplementary Movie 2) β-gal−/− mice had an
ataxic gait, with a stiff, curled tail, as if it were being used for balance.
At 9months of age, both female (Supplementary Movie 3) and male
(Supplementary Movie 4) β-gal−/− mice displayed a severe neurolo-
gical deterioration, manifesting as physical instability and labored
ambulation. As the disease progressed, neurological symptoms of β-
gal−/− mice significantly worsened, leading to a loss of function in
their forelimbs and hindlimbs and subsequently became paralyzed.
In agreement with previous mouse models of GM1-gangliosidosis, β-
gal−/− mice had a significantly shortened lifespan compared to wild-
type and heterozygous animals, which have an average lifespan over
2 years. In females, the lifespan of β-gal−/− mice was
264.4 ± 34.9 days (mean ± standard deviation) (Fig. 3C). Likewise,
the lifespan of male β-gal−/− mice was 265.2 ± 21.2 days (Fig. 3D).
One wildtype mouse required euthanasia at 350 days due to injuries
sustained from fighting.
In contrast, Glb1W274L mice displayed no observable phenotype over
the course of one year. Detailed histopathology examination of 8-week
old mice showed no abnormalities. Skeletal X-rays showed no
morphological abnormalities, and quantification of keratan sulfate in
plasma was not increased compared to control mice (data not shown).
Additionally, both female (Fig. 3E) and male (Fig. 3F) mice weights did
not differ from wildtype and heterozygous mice. Not surprisingly,
Glb1W274L mice showed no increase in mortality (Fig. 3G-H). Because of
the lack of a visible phenotype, no further characterization of the
Glb1W274L line will be discussed here.
3.3. Ganglioside accumulation in β-gal−/− mouse brains
To determine whether the deficiency in β-gal enzyme activity re-
sulted in ganglioside accumulation, high-performance liquid chroma-
tography, tandem mass spectrometry was implemented to quantify
GM1 and GA1 gangliosides in β-gal−/− brains. As the 18‑carbon atom
sphingosine chain length is the most abundant GM1 and GA1 ganglio-
side [34], this was chosen as the biomarker for quantification. In the
cerebral cortex, there was a 1.6-fold increase in GM1 ganglioside
compared to control animals, where GA1 ganglioside was increased 2.5-
fold (Fig. 4A). In the cerebellum GM1 and GA1 ganglioside content was
4.0-fold and 7.3-fold higher than controls, respectively (Fig. 4B). Fur-
ther, in the hippocampus, GM1 ganglioside was 2.2-fold higher than
controls, in addition to a 3.6-fold increase in GA1 ganglioside (Fig. 4C).
In addition to quantifying the primary substrate of β-gal, the sec-
ondary accumulation of GM2 and GM3 ganglioside was measured. In all
three brain regions analyzed, secondary ganglioside accumulation was
significantly increased, except in the case of GM3 ganglioside in the
cerebellum. In the cerebral cortex, GM2 ganglioside accumulation was
2.6-fold higher than wildtype, while there was a 4.5-fold increase of
GM3 ganglioside (Fig. 4A). In the cerebellum, GM2 ganglioside content
was 1.5-fold higher than controls and GM3 ganglioside was increased
1.8-fold (Fig. 4B). In the hippocampus, the amount of GM2 ganglioside
was increased 2.6-fold and GM3 ganglioside was increased 2.4-fold
(Fig. 4C).
Histopathological examination of the CNS in β-gal−/− mice re-
vealed a striking and widespread marked swelling and enlargement of
neurons with pale, finely granular to foamy cytoplasm that occasionally
displaced the nucleus to the periphery. Neuronal cytoplasmic vacuo-
lation was variable, and was observed within the cerebral cortex, tha-
lamus, Cornu Ammonis (mainly CA3) of the hippocampus, brainstem
nuclei, cerebellum (Purkinje cells and deep cerebellar nuclei), and
spinal cord (ventral and dorsal spinal horns) (Fig. 5). These findings are
consistent with the CNS findings for β-gal−/− mice described pre-
viously [11,12], are characteristic findings in the of the lysosomal
disease GM1-gangliosidosis in the brain, and were absent in control
mice. In addition, although negative with PAS, toluidine blue, and al-
cian blue stains, affected neurons stained positively for Luxol fast blue
(Fig. 6), as has been described in several animal models of gang-
liosidoses [35,36]. In addition to the CNS findings, we also observed
cellular enlargement with cytoplasmic vacuolation involving hepato-
cytes of the liver, acinar cells of the pancreas, and enterocytes of the
intestine (Supplementary Fig. 1).
3.4. Severe neuromotor deficiencies in β-gal−/− mice
At 6months of age, neuromotor function was tested using several
behavioral tests. First, β-gal−/− mice were subjected to the balance
beam. Both female (Fig. 7A) and male (Fig. 7B) β-gal−/− mice took
significantly longer to cross the 25mm square beam on all 4 test days
compared to heterozygous and wildtype mice. In addition to a longer
latency to cross the beam, β-gal−/− mice had significantly more hin-
dlimb foot slips while crossing the beam (Fig. 7C & D). On Day 4, an-
imals were subjected to beams of increasing difficulty. Again, β-gal−/−
mice took significantly longer to cross the beams compared to control
mice (Fig. 7E & F) and the number of foot slips was elevated (Fig. 7G &
H), indicating that β-gal−/− mice had a severe motor coordination
deficit.
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The second test of neuromotor function was the accelerating ro-
tarod, which tests motor coordination and motor learning. Over the
3 days of trials, the latency to fall of both female (Fig. 8A) and male
(Fig. 8B) β-gal−/− mice was significantly lower than heterozygous and
wildtype mice. Additionally, β-gal−/− showed an inability to learn to
stay on the rotarod between trial days, whereas control animals
Fig. 3. Weight and survival analysis of β-galactosidase deficient mice. (A and B) Weight of β-gal−/−mice over one year (n > 5 for each group, except mutant males
at timepoint week 41 where n=1). (C and D) Kaplan-Meier survival curve of β-gal−/− mice (n=5–8 for each group). (E and F) Weight of Glb1W274L mice over one
year (n > 6 for each group). (G and H) Kaplan-Meier survival curve of Glb1W274L mice (n=7–16 for each group). Weight data are mean ± SEM. *p≤ 0.05,
**p≤ 0.01, ****p≤ 0.0001. β-gal−/− survival significantly reduced ****p≤ 0.0001.
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Fig. 4. Ganglioside quantification in brain tissue of β-gal−/−mice. GM1, GA1, GM2, and GM3 gangliosides accumulation in the (A) cerebral cortex, (B), cerebellum,
and (C) hippocampus of mice (n=3 for each group) were measured using high performance liquid chromatography tandem-mass spectrometry. Data are reported as
the peak area ratios of analytes in the sample to the corresponding internal standard. Data are mean ± SEM. *p≤ 0.05, ****p≤ 0.0001.
Fig. 5. Widespread marked enlargement of neurons with cytoplasmic vacuolation (reflecting significant accumulation of storage material) in the central nervous
system of β-gal−/− mice. Hematoxylin and eosin staining of brain and spinal cord of β-gal−/− and control mice. Brain and spinal cord (β-gal−/−): objective x40,
scale bar indicates 30 μm; spinal cord control: objective x60, scale bar indicates 20 μm.
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improved their latency to fall on subsequent days. Overall, this test
supported the finding that β-gal−/− mice have severe motor co-
ordination deficiencies, in addition to a lack of motor learning.
Thirdly, the pole test was utilized to assess bradykinesia, typically
observed in other CNS diseases such as Parkinson's disease (reviewed in
[37]). In both β-gal−/− females (Fig. 8C) and males (Fig. 8D), the in-
version time was significantly longer than heterozygous and wildtype
mice. Similar results were seen in the total descent time. Female
(Fig. 8E) and male (Fig. 8F) β-gal−/− mice took significantly longer, or
could not complete the initial inversion task to descend the pole,
compared to heterozygous and wildtype mice, who could complete the
task with relative ease.
The last test used to analyze neuromotor function was the inverted
screen test to measure grip strength. The latency to fall of female β-
gal−/− mice averaged 17.6 ± 3.7 s, where heterozygous and wildtype
mice could remain on the inverted screen for 59.1 ± 0.6 s and
57.4 ± 1.2 s, respectively (Fig. 8G). Male β-gal−/− mice showed a
similar significant loss of grip strength, only being able to stay on the
screen for 3.4 ± 0.5 s, compared to 53.4 ± 2.9 s in heterozygous
mice, and 49.9 ± 2.4 s in wildtype mice (Fig. 8H). In summation, the
results of this test and the extensive behavior tests of motor function
showed that β-gal−/− mice have severe neuromotor impairments.
3.5. Impaired neurocognitive function of β-gal−/− mice
Previous studies from our group have shown that cognition is sig-
nificantly impaired in mouse models of other lysosomal diseases
[38,39]. To test the spatial reference memory of β-gal−/− animals, the
Barnes maze was implemented. Over the course of 4 days of testing, the
latency to escape the platform of wildtype and heterozygous animals
progressively decreased in females from 158.7 ± 9.6 and
159.9 ± 10.0 s on Day 1 to 42.4 ± 5.4 and 35.1 ± 5.0 s on Day 4
(Fig. 9A). Similarly, in males, the latency to escape decreased from
176.9 ± 2.4 s in wildtype and 180 s in heterozygous mice on Day 1 to
38.2 ± 2.5 s and 42.0 ± 10.8 s on Day 4 (Fig. 9B). These results in-
dicate a normal cognitive function. In comparison, the latency to escape
of female and male β-gal−/− mice latency to escape decreased from
180 s for both groups to 177.3 ± 1.8 s and 175.3 ± 4.8 s, respectively.
The absence of a decrease in latency to escape suggested that β-gal−/−
mice have a learning disability and impaired spatial reference memory.
Additionally, the spatial working memory of β-gal−/− animals was
tested using the spontaneous alternating T-maze. This test utilizes the
normal tendencies of mice to explore a new environment. If an animal's
cognition is impaired, mice will not alternate between arms on sub-
sequent trials, resulting in a random pattern of arm choices (≤50%
successful alternation). In this test, female wildtype and heterozygous
mice successfully alternated 72.9 ± 2.4% and 75.0 ± 1.9% of the
trials, while β-gal−/− mice correctly alternated 47.9 ± 5.9% of the
time (Fig. 9C). Similarly, male wildtype and heterozygous mice suc-
cessfully alternated 74.3 ± 2.8% and 68.8 ± 1.8% of the trials, where
β-gal−/− mice correctly alternated 42.0 ± 8.5% of the trials (Fig. 9D).
These results suggested the decision of β-gal−/− mice was random,
indicating a spatial working memory deficiency.
4. Discussion
β-galactosidase is a unique lysosomal hydrolase, in that when it is
deficient, depending on where the mutation is located in the GLB1 gene
and what effect it has on β-gal enzyme activity, it is responsible for two
distinct lysosomal diseases: one affecting the central nervous system
(GM1-gangliosidosis), and another affecting the skeletal system
(Morquio syndrome type B). Recently, our group applied bioinformatic
tools to investigate the structure of the β-gal enzyme and provided
important inferences about why mutations in one gene can lead to two
different diseases [40]. In this paper, we describe two novel murine
models of β-galactosidase deficiencies that were developed by using
CRISPR-Cas9 genome editing in a single experiment. By utilizing a
donor oligonucleotide, homology-directed DNA repair was promoted to
introduce a 2 bp substitution commonly found in patients suffering
from Morquio syndrome type B [4–7,9]. This mutation, GLB1W273L,
occurs in a highly conserved region of the GLB1 gene. The tryptophan
residue is predicted to be important for the secondary structure of β-
galactosidase [32], and when mutated, reduces the ability of the en-
zyme to catabolize keratan sulfate, resulting in Morquio syndrome type
B. Here we have described the introduction of this 2 bp mutation into
mice (Glb1W274L). Similar to what has been described in Morquio syn-
drome type B patients, the presence of a β-gal enzyme deficiency was
observed. While residual β-gal enzyme activity was present, it ranged
between 8.4 and 13.3% of wildtype levels, depending upon the tissue
assayed. However, even though β-gal enzyme activity is diminished,
after one year, Glb1W274L mice show no observable skeletal phenotype.
An explanation of this observation may be due to the absence of keratan
sulfate in skeletal tissues of mice [41]. However, keratan sulfate-con-
taining proteoglycans are present within the cornea of the mouse,
Fig. 6. Histopathological images of Luxol fast blue-stained brain tissue from β-
gal−/− mice compared with control mice. Neurons of β-gal−/− mice are en-
larged/swollen, and contain abundant intracytoplasmic, granular, Luxol fast
blue positive material, with occasional nuclear peripheralization. Objective
x40, scale bar indicates 30 μm.
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beginning around postnatal day 20 [42,43]. Further studies will have to
be conducted to determine whether the reduction in β-gal activity re-
sults in a corneal phenotype.
In the second model, a 20 bp deletion was introduced into exon 8 of
the β-gal encoding gene as a result of non-homologous end joining DNA
repair. This mutation resulted in the deletion of a highly conserved
region of DNA, including the catalytic nucleophile (Glb1Glu269) of the β-
gal enzyme. While there have been no patients with a mutation re-
sulting in a loss of the catalytic nucleophile described, this mutation is
predicted to result in both Morquio syndrome type B and GM1-gang-
liosidosis, as a catabolic reaction could not occur [44]. In our mouse
model, the 20 bp mutation results in a complete loss of β-gal enzyme
activity and subsequent accumulation of the primary storage materials
GM1 ganglioside and its asialo derivative GA1 ganglioside in the central
nervous system as shown by histopathology and ganglioside quantifi-
cation. An alternative pathway of GM1 ganglioside catabolism exists
apart from GM1 ganglioside to GA1 ganglioside conversion by neur-
aminidase. In the presence of ceramide deacylase, GM1 ganglioside can
be converted to lyso-GM1, which has been shown to be elevated in
patients with GM1-gangliosidosis [45]. It is believed that lyso-GM1 is
also neuropathic, similar to other toxic lysosphingolipids like galacto-
sylsphingosine and glucosylsphingosine in Krabbe and Gaucher dis-
eases, respectively. Further, secondary accumulation of glyco-
sphingolipids such as glucosylceramide, lactosylceramide, GM2, GM3,
Fig. 7. Impaired balance and motor coordination β-gal−/− mice. At 6months of age, β-gal−/− mice were tested on a balance beam. (A and B) Latency to cross beam
and (C and D) number of hindlimb foot slips while crossing the beam. (E and F) Latency to cross beams of increasing difficulty and (G and H) number of hindlimb foot
slips while crossing the beam on test day (n=5–8 for each group). Data are mean ± SEM. **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001.
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and GD1a gangliosides in GM1-gangliosidosis patients has been re-
ported [46–48]. In the β-gal−/− mouse model reported here, a sig-
nificant secondary accumulation of GM2 and GM3 gangliosides in the
brain was observed. Overall, the accumulation of gangliosides resulted
in progressive severe neuromotor decline, similar to what was pre-
viously described [13,14]. Additionally, β-gal−/− mice showed a se-
vere neurocognitive impairment not previously described. Further,
these impairments led β-gal−/− mice to become sick and lose a sig-
nificant amount of weight beginning around 29weeks in females and
25 weeks in males. Eventually, β-gal−/−mice succumbed to the disease
by 10months of age.
Prior to this publication, the only mouse models of β-galactosidase
deficiency that existed were those generated using the time-consuming
ES cell approach that utilizes the introduction of an exogenous neo-
mycin resistance gene sequence to interrupt Glb1 gene expression.
However, their use in β-galactosidase deficiency studies is likely limited
to studying enzyme replacement therapies [49] or gene therapies
[13,14,50,51]. However, most patients who suffer from GM1-gang-
liosidosis or Morquio syndrome type B do not have a complete β-gal
enzyme deficiency. In reality, many patients with juvenile or adult
onset GM1-gangliosidosis or Morquio syndrome type B have a single
amino acid substitution that affects the secondary or tertiary structure
of β-gal, reducing its catalytic activity. With the creation of the
Glb1W274L model described in this manuscript, the ability to test en-
zyme-stabilizing small molecules becomes a possibility. A second po-
tential limitation of the previous models of GM1-gangliosidosis is the
Fig. 8. Significant motor deficiency and loss of strength in β-gal−/− mice. (A and B) Rotarod testing (n=5–8 for each group), (CeF) pole test (n= 5–8 for each
group), and (G and H) inverted screen testing (n=5–11 for each group) carried out at 6 months of age. Data are mean ± SEM. ****p≤ 0.0001.
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possibility of a random mutation arising in the modified Glb1 locus that
results in the introduction of a novel splice site, causing skipping of the
exon encoding the neomycin gene. The result of this would be a shor-
tened amino acid sequence, but could potentially yield a catalytically
active β-gal enzyme. In the model described here, the possibility of this
occurring is nonexistent, because the amino acid responsible for the
catalytic activity of the enzyme (Glb1Glu269) has been removed. One
potential limitation of the models described here, though, could be that
they were derived on a pure C57BL/6J background, thus the results of
experiments conducted on these animals may not be recapitulated in
other genetically different strains of mice. However, it is postulated that
this will not be an issue due to the fact that the previously described
models developed on alternative genetic backgrounds show similar
phenotypes to those described here. Future studies, including pro-
teomics [52] and metabolomics [53], could be applied to further
characterize these models and study the etiology of these diseases.
In conclusion, we have described the use of CRISPR-Cas9 genome
editing to develop two new models of β-galactosidase deficiency. The
first model recapitulates the enzyme deficiency observed in Morquio
syndrome type B patients, which is the first description of a mouse
model to have residual β-gal enzyme activity. In the second model,
many characteristics of infantile GM1-gangliosidosis are displayed.
Overall, these mice will be essential for the future development and
testing of novel therapies for Morquio syndrome type B and GM1-
gangliosidosis.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2018.11.002.
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